Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review

Mirza, Myriam; Goerke, Lutz; Anderson, Anna; Wilsdon, Tim

doi:10.1016/j.jval.2024.04.023

Value in Health

2024

DOI: 10.1016/j.jval.2024.04.023

|View full text |Cite

Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review

Myriam Mirza,

Lutz Goerke,

Anna Anderson

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review

Ferreira-Gonzalez,

Ko,

Fusco

et al. 2024

Future Oncology

View full text Add to dashboard Cite

Aim: Next-generation sequencing (NGS) of solid tumors can inform treatment decisions; however, uptake remains low. This objective of this systematic review was to identify barriers to and facilitators of NGS in US oncology settings. Materials & methods: Embase and MEDLINE were searched in March 2023 for articles published from 2012 to 2023 on barriers and facilitators of NGS adoption for solid tumors. Surveys, interviews and observational studies were eligible. Studies on genetic testing for hereditary cancers and non-US studies were excluded. The Motheral scale, Joanna Briggs Institute critical appraisal checklist and McGill Mixed Methods Appraisal Tool were used to assess study quality. Data were synthesized narratively. Results: Twenty-one studies were included. Study participants were clinicians, payers and administrators. Key barriers included complex reimbursement processes and uncertainties around clinical utility. Including recommendations for NGS in clinical practice guidelines was a key facilitator, although insurance policies were often more restrictive than guideline recommendations. Conclusion: Uptake of NGS is increasing but barriers remain. Changes to the current reimbursement frameworks are needed to increase access to NGS. The impact of implementing the 2018 National Coverage Determination, which allows access to NGS for all Medicare beneficiaries with advanced cancer, is not yet evident in the published literature.

show abstract

Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review

Ferreira-Gonzalez,

Ko,

Fusco

et al. 2024

Future Oncology

View full text Add to dashboard Cite

show abstract

Potential barriers to implementation of next-generation sequencing in cancer management: a U.S. Physician-based survey

Hussain,

Szamreta,

Ning

et al. 2024

Future Oncology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review

Cited by 2 publications

References 39 publications

Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review

Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review

Potential barriers to implementation of next-generation sequencing in cancer management: a U.S. Physician-based survey

Contact Info

Product

Resources

About